AKESO Surges Over 5% in Early Trading as Second Indication for Self-Developed Gumokimab Receives NDA Acceptance

Deep News10:26

AKESO (09926) rose more than 5% in early trading. At the time of writing, the stock was up 5.25% to HK$118.30, with a turnover of HK$377 million.

According to an announcement on AKESO's official WeChat account, the company recently announced that the new drug application (sNDA) for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This signifies that the drug has the potential to provide a new treatment option for nearly 4 million AS patients in China.

Gumokimab is reportedly AKESO's third major non-oncology product to reach the marketing application stage, following Inusimab (PCSK9) and Iruximab (IL-12/IL-23). With the successive launches of Inusimab and Iruximab and their inclusion in the National Reimbursement Drug List, alongside products like Gumokimab and Mandomab progressively entering the commercialization phase, and the efficient advancement of deep development for multiple indications of non-oncology innovative targeted drugs such as the IL-4R/ST2 bispecific antibody and treatments for neurodegenerative diseases, the company's product portfolio is growing increasingly robust, and the competitiveness of its non-oncology segment continues to strengthen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116688046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116688046","market":"us","top_or_hot":-1,"title":"AKESO Surges Over 5% in Early Trading as Second Indication for Self-Developed Gumokimab Receives NDA Acceptance","media":"Deep News","content":"<p>AKESO (09926) rose more than 5% in early trading. At the time of writing, the stock was up 5.25% to HK$118.30, with a turnover of HK$377 million.</p>\n<p>According to an announcement on AKESO's official WeChat account, the company recently announced that the new drug application (sNDA) for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This signifies that the drug has the potential to provide a new treatment option for nearly 4 million AS patients in China.</p>\n<p>Gumokimab is reportedly AKESO's third major non-oncology product to reach the marketing application stage, following Inusimab (PCSK9) and Iruximab (IL-12/IL-23). With the successive launches of Inusimab and Iruximab and their inclusion in the National Reimbursement Drug List, alongside products like Gumokimab and Mandomab progressively entering the commercialization phase, and the efficient advancement of deep development for multiple indications of non-oncology innovative targeted drugs such as the IL-4R/ST2 bispecific antibody and treatments for neurodegenerative diseases, the company's product portfolio is growing increasingly robust, and the competitiveness of its non-oncology segment continues to strengthen.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AKESO Surges Over 5% in Early Trading as Second Indication for Self-Developed Gumokimab Receives NDA Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAKESO Surges Over 5% in Early Trading as Second Indication for Self-Developed Gumokimab Receives NDA Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-23 10:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO (09926) rose more than 5% in early trading. At the time of writing, the stock was up 5.25% to HK$118.30, with a turnover of HK$377 million.</p>\n<p>According to an announcement on AKESO's official WeChat account, the company recently announced that the new drug application (sNDA) for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This signifies that the drug has the potential to provide a new treatment option for nearly 4 million AS patients in China.</p>\n<p>Gumokimab is reportedly AKESO's third major non-oncology product to reach the marketing application stage, following Inusimab (PCSK9) and Iruximab (IL-12/IL-23). With the successive launches of Inusimab and Iruximab and their inclusion in the National Reimbursement Drug List, alongside products like Gumokimab and Mandomab progressively entering the commercialization phase, and the efficient advancement of deep development for multiple indications of non-oncology innovative targeted drugs such as the IL-4R/ST2 bispecific antibody and treatments for neurodegenerative diseases, the company's product portfolio is growing increasingly robust, and the competitiveness of its non-oncology segment continues to strengthen.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1116688046","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116688046","pubTimestamp":1769135178,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"AKESO (09926) rose more than 5% in early trading. At the time of writing, the stock was up 5.25% to HK$118.30, with a turnover of HK$377 million. According to an announcement on AKESO's official...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1574":"生物医药B类股","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","09926":"康方生物","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金"},"translate_title":"自研古莫奇单抗第二个适应症获NDA受理康方生物早盘大涨超5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO (09926) rose more than 5% in early trading. At the time of writing, the stock was up 5.25% to HK$118.30, with a turnover of HK$377 million.\nAccording to an announcement on AKESO's official WeChat account, the company recently announced that the new drug application (sNDA) for its self-developed novel humanized anti-IL-17A monoclonal antibody, Gumokimab (AK111), for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This signifies that the drug has the potential to provide a new treatment option for nearly 4 million AS patients in China.\nGumokimab is reportedly AKESO's third major non-oncology product to reach the marketing application stage, following Inusimab (PCSK9) and Iruximab (IL-12/IL-23). With the successive launches of Inusimab and Iruximab and their inclusion in the National Reimbursement Drug List, alongside products like Gumokimab and Mandomab progressively entering the commercialization phase, and the efficient advancement of deep development for multiple indications of non-oncology innovative targeted drugs such as the IL-4R/ST2 bispecific antibody and treatments for neurodegenerative diseases, the company's product portfolio is growing increasingly robust, and the competitiveness of its non-oncology segment continues to strengthen.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116688046","isCrawlerRequest":true}